ERRATUM

Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539

TO THE READERSHIP: An error appeared in the article by Rogers et al. (Rogers L, Zhang P, Vogelbaum MA, et al: Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. *J Neurosurg* 129:35–47, 2018).

Within Fig. 1, Group 2 (Intermediate Risk) was erroneously noted to include patients with a newly diagnosed subtotally resected (STR) WHO Grade II tumor. These patients were not enrolled in Group 2, rather they were included in Group 3 (High Risk). The correct figure is shown below.

The authors apologize to the readership for this error.

The article has been corrected online as of September 28, 2018.

Leland Rogers, MD¹

Peixin Zhang, PhD²

Michael A. Vogelbaum, MD, PhD³

Minesh P. Mehta, MD⁴

On behalf of the authors

¹Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

²NRG Oncology Statistics and Data Management Center, Philadelphia, PA

³Cleveland Clinic Foundation, Cleveland, OH

⁴Miami Cancer Institute Executive Office, Miami, FL

INCLUDE WHEN CITING

Published online September 28, 2018; DOI: 10.3171/2018.8.JNS161170a.

©AANS 2018, except where prohibited by US copyright law

Phase II Trial of Observation for Low-Risk Meningioma and of Radiotherapy for Intermediate and High-Risk Meningioma

Opened June 19, 2009

Required Sample Size: 165
55 for each group

Patients enrolled:

Group 1: 65 (closed 9.29.2010)
Group 2: 56 (closed 5.12.2011)
Group 3: 57 (closed 8.24.2012)

Average Monthly Accrual:

Group 1: 4.2
Group 2: 2.5
Group 3: 1.5

Group 1 (Low Risk)

New WHO Grade I, GTR or STR

Group 2 (Intermediate Risk)

Recurrent WHO Grade I, GTR or STR
New WHO Grade II, GTR

Group 3 (High Risk)

Any WHO Grade III, GTR or STR
Recurrent WHO Grade II, GTR or STR
New WHO Grade II, STR

FIG. 1. Protocol schema, accrual data, and subgroup definitions.